EBTATE is under clinical development by Molecular Targeting Technologies and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EBTATE’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EBTATE overview

177-Lu-DOTA-EB-TATE is under development for the treatment of neuroendocrine tumors, Hurthle cell thyroid cancer and nasopharyngeal cancer. 177Lu-DOTA-TATE is administered as an intravenous infusion. The drug candidate is a radioconjugate consisting of somatostatin analog octreotide conjugated to radioisotope 177 lutetium via the chelator 1,4,7,10- tetraazacyclododecane-N,N’,N”, N”’-tetraacetic acid (DOTA). The drug candidate acts by targeting Somatostatin Receptor Type 2.

Molecular Targeting Technologies overview

Molecular Targeting Technologies (MT Target) is a biotechnology company that acquires and develops novel technologies for treatment and diagnosis of human diseases. The company offers flow cytometry, small molecule drug conjugates (SMDC), MRI and nuclear imaging agents, optical imaging agents, dyes for bioconjugation, immobilized steroid beads, bioactives, crosslinkers, magnetic beads, blood vessel labelling kits, lipophilic cynanines and custom chemistry services. It develops human anti-rabies monoclonal antibody (Mab) for post-exposure treatment of rabies, which is in phase II clinical stage. The company also offers duramycin and duramycin-nir790 conjugate. MTTI is headquartered in West Chester, Pennsylvania, the US.

For a complete picture of EBTATE’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.